In this special episode of Lung Cancer Considered, hosts Dr. Stephen Liu and Dr. Narjust Florez discuss the seminal IPASS trial with its principal investigator, Dr. Tony Mok. IPASS was a randomized phase III trial that compared the EGFR TKI gefitinib to carboplatin plus paclitaxel and showed, for the first time, that in a selected population, targeted therapy was superior to chemotherapy. The initial results were published in the New England Journal of Medicine in 2009 and helped usher in the era of precision oncology. Dr. Tony Mok is the Li Shu Fan Medical Foundation endowed Professor and Chairman of the Department of Clinical Oncology at the Chinese University of Hong Kong. He cofounded the Lung Cancer Research Group, Chinese Thoracic Oncology Research Group and Asia Thoracic Oncology Research Group.

IASLC IPASS Study 2

Should More $ Be Spent on Medical Research For Rare Conditions? Shepard challenges a popular opinion. Chris, of Special Books by Special Kids (SBSK), is awesome, and Shepard loves his channel, but...

Please subscribe to my youtube channel: https://www.youtube.com/@shepardthinks  :)
Learn about Voluntaryism at http://openlyvoluntary.com/

Should More $ Be Spent On Medical Research For Rare Conditions? SBSK

Voice123

Do something incredible for Arcturus Therapeutics

STAMPEDE is a long-running trial in advanced prostate cancer, in which nearly 12,000 men have taken part. Thanks to its multi-arm multi-stage platform design, STAMPEDE has tested many different treatments and directly led to improvements in the standard of prostate cancer care several times. 

This Trial Talk podcast mini-series will explore the trial’s journey from its inception in the early 2000s to the end of patient recruitment in March 2023. 

Part 1 covers the landscape of prostate cancer treatment before STAMPEDE, as well how the trial was designed, featuring two researchers who lead the methodological and clinical sides of the trial: Max Parmar, Professor of Medical Statistics and Epidemiology and Director of the MRC Clinical Trials Unit at UCL and UCL's Institute of Clinical Trials and Methodology, and Nick James, Professor of Prostate and Bladder Cancer Research at the Institute of Cancer Research.

-

Further information is available on the STAMPEDE study page at www.mrcctu.ucl.ac.uk

For questions or feedback on the series, message us at mrcctu.engage@ucl.ac.uk

For more information and to access the transcript: https://bit.ly/3OQWhV8

As a listener, your opinion is very valuable to us. Please help us to improve the podcast in future by filling in this short survey: forms.office.com/e/PjfjQ5Mn6g

STAMPEDE (part 1): A new era for prostate cancer research with Max Parmar & Nick James

DYK that one-quarter to one-half of all hospital waste is generated by the OR? Dr. Paige Fox, an Associate Professor in our Division of Plastic and Reconstructive Surgery is trying to change that. She talks to us about her endeavor to green the OR using a method that she has shown works in different hospital settings and for different types of operations.

In addition to her sustainability work, Dr. Fox also operates a wet lab doing basic science and is the Director of Stanford’s PRS Residency Program. She gives us an update on her biosensor collaboration with Stanford School of Engineering legend Dr. Zhenan Bao (https://www.nature.com/articles/s41928-018-0071-7) and has advice for MS4s entering Match 2024.

Greening the OR with Dr. Paige Fox

STAMPEDE is a long-running trial in advanced prostate cancer, in which nearly 12,000 men have taken part. Thanks to its multi-arm multi-stage platform design, STAMPEDE has tested many different treatments and directly led to improvements in the standard of prostate cancer care several times. 

This Trial Talk podcast mini-series will explore the trial’s journey from its inception in the early 2000s to the end of patient recruitment in March 2023. 

Part 2 is about patient and public involvement (PPI) in the trial. David Matheson, a Reader at the University of Wolverhampton and STAMPEDE patient representative, shares his insight into the work this entails and why it is so important to champion the voices of patients. We also hear about PPI from the perspective of trial researchers, Max Parmar and Nick James.

-
Further information is available on the STAMPEDE study page at www.mrcctu.ucl.ac.uk

For questions or feedback on the series, message us at mrcctu.engage@ucl.ac.uk

For more information and to access the transcript: bit.ly/3OQWhV8

As a listener, your opinion is very valuable to us. Please help us to improve the podcast in future by filling in this short survey: forms.office.com/e/PjfjQ5Mn6g

STAMPEDE (part 2): The role of the patient voice with David Matheson, Max Parmar & Nick James

STAMPEDE is a long-running trial in advanced prostate cancer, in which nearly 12,000 men have taken part. Thanks to its multi-arm multi-stage platform design, STAMPEDE has tested many different treatments and directly led to improvements in the standard of prostate cancer care several times. 

This Trial Talk podcast mini-series will explore the trial’s journey from its inception in the early 2000s to the end of patient recruitment in March 2023. 

In the final part, Max Parmar and Nick James look back over the trial’s impact on clinical practice and platform trial design and look forward to STAMPEDE2, sharing their hopes for the future of prostate cancer research. 

-

Further information is available on the STAMPEDE study page at www.mrcctu.ucl.ac.uk

For questions or feedback on the series, message us at mrcctu.engage@ucl.ac.uk

For more information and to access the transcript: bit.ly/3OQWhV8

As a listener, your opinion is very valuable to us. Please help us to improve the podcast in future by filling in this short survey: forms.office.com/e/PjfjQ5Mn6g

STAMPEDE (part 3): Impact and legacy with Max Parmar & Nick James

In the first episode of our new Trial Talk series, Hanif Esmail and Conor Tweed take over the microphones to interview Andrew Nunn and Sarah Meredith, who have both recently retired from the Unit, having spent a combined total of 92 years working in the field of tuberculosis (TB). 

As we celebrate Andrew and Sarah’s long and accomplished careers, we’ll dive into the history of TB clinical trials and muse on the future of TB research.

For more information and to access the transcript: https://www.mrcctu.ucl.ac.uk/news/news-stories/2024/january/new-podcast-episode-careers-in-tb-clinical-trials/ 

Check out our earlier podcast episodes about TB trials, also featuring Andrew Nunn:
• https://soundcloud.com/trial-talk-podcast/the-stream2-trial-how-should-we-treat-multi-drug-resistant-tuberculosis?si=013c930cbd184b7a93b64eb7101e57be&utm_source=clipboard&utm_medium=text&utm_campaign=social_sharing
• https://soundcloud.com/trial-talk-podcast/andrew-nunn-talks-medical-statistics-tb-and-algerian-nomads-part-1?si=6b8c8c2da31a45fba323adbdd97c1f1b&utm_source=clipboard&utm_medium=text&utm_campaign=social_sharing
• https://soundcloud.com/trial-talk-podcast/andrew-nunn-talks-medical-statistics-tb-and-algerian-nomads-part-2?si=1723fbebd5d746079dddb12a139f0eed&utm_source=clipboard&utm_medium=text&utm_campaign=social_sharing 

For questions or feedback on the series, message us at mrcctu.engage@ucl.ac.uk

As a listener, your opinion is very valuable to us. Please help us to improve the podcast in the future by filling in this short survey: forms.office.com/e/PjfjQ5Mn6g

Careers in TB trials with Andrew Nunn and Sarah Meredith

A saliva test has shown promising results in detecting breast cancer. In a test phase, the testing device accurately made the distinction between healthy breast tissue, early breast cancer and advanced breast cancer.

Radio ARA Programme du 2024-02-22

What's right: scientists develop a groundbreaking test for breast cancer screening

An estimand is a description of the research question a trial seeks to answer, which can help researchers better understand how their study should be designed and analysed. Estimands also provide a clear way to communicate treatment effects to different stakeholders.

This episode of the Trial Talk podcast features Principal Research Fellow Brennan Kahan, exploring how triallists could benefit from using estimands. Brennan also discusses his recent paper which aims to demystify new guidance on the use of estimands.

Resources:
•The estimands framework: a primer on the ICH E9(R1): https://www.bmj.com/content/384/bmj-2023-076316 
•'We must let the research question drive study methods' opinion piece: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908044/ 
•Estimands in cluster-randomized trials: choosing analyses that answer the right question: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908044/ 

For more information and to access the transcript: bit.ly/4dazsWF

For questions or feedback on the podcast series, message us at mrcctu.engage@ucl.ac.uk

As a listener, your opinion is very valuable to us. Please help us to improve the podcast in the future by filling in this short survey: forms.office.com/e/PjfjQ5Mn6g

Estimands: Answering the right research questions

How does our understanding of genetics shape the health of the public?

In this month’s episode, our experts dive into the exciting world of genetics, exploring the latest technological breakthroughs and innovations. They discuss not only the value of these advancements but also the ethical considerations surrounding them, particularly in how they can enhance the health of the public.

Dr Adam Rutherford (bestselling author, broadcaster and lecturer in genetics and society at UCL) shares his wealth of knowledge on the evolution of genetics, and the common misconceptions that persist in the field. Adam delves into the historical context of genetics and its entanglement with eugenics, reminding us of the ethical considerations that must accompany scientific advancement.

Prof George Davey Smith, a clinical epidemiologist and director of the MRC Integrative Epidemiology Unit, discusses the impact of genetics on the health of the public. He highlights the potential of genetic data to revolutionise healthcare and offers a critical perspective on the consumer genetics market. 

Listen for an in depth look at the complexities of genetic diseases, the implications for health policy, and the ethical dimensions of genetic research. 

Public Health Disrupted with Rochelle Burgess and Xand Van Tulleken is produced by Annabelle Buckland at Decibelle Creative / @decibelle_creative

Season 4 - The genetic revolution: implications and applications for improving public health

Research News from the Wellcome Sanger Institute

Source of pregnancy complications from infections revealed by placenta map 3 May 2024

The MRC Clinical Trials Unit at UCL is committed to actively involving patients and the public in our trials. All our Patient and Public Involvement (PPI) work is overseen by our PPI Group, made up of MRC CTU staff alongside seven patient representatives, with a wide range of experience in different areas. 

In this episode of the Trial Talk podcast, two members of the Unit’s PPI Group, Richard Stephens and Ian Newsome, discuss what PPI means to them, how they got involved as patient representatives in clinical research, and how the MRC CTU at UCL embeds PPI into our trials.

Resources:
• Our PPI group:  https://www.mrcctu.ucl.ac.uk/patients-public/patient-and-public-involvement/about-our-ppi-group/ 
• PPI resources: https://www.mrcctu.ucl.ac.uk/patients-public/patient-and-public-involvement/ppi-resources/ 
• Testing Treatments: Better Research for Better Healthcare (book): https://www.ncbi.nlm.nih.gov/books/NBK66204/ 

For more information and to access the transcript: https://bit.ly/3KlKtak

For questions or feedback on the podcast series, message us at mrcctu.engage@ucl.ac.uk

As a listener, your opinion is very valuable to us. Please help us to improve the podcast in the future by filling in this short survey: forms.office.com/e/PjfjQ5Mn6g

Patient and Public Involvement (PPI) in clinical trials

The new drug Dostarlimab guides the body's immune system to recognise the cancer cells as harmful and kill them. Patients who followed the six months of treatment showed a complete clinical response with no evidence of tumours during follow-up exams.

Radio ARA Programme du 2024-06-13

What's right: new rectal cancer drug shows 100% positive response

The Department of Surgery at Stanford University

Musicien, j’ai fait des études de communication/marketing et de réalisation sonore. 

Captivé entre autres par la voix off 🎙️ et l’univers du son, je travaille actuellement sur des projets à destination des médias, en parallèle de l’accompagnement de classes de collèges en éducation musicale. 

Je cherche à capitaliser cette expérience dans la réalisation sonore et l’écriture au profit d’acteurs de la production audiovisuelle, qui représentent pour moi une source d'inspiration et d'intérêt.

Europe's best independent music station based in Luxembourg! English speaking.

We apply and explore genomic technologies at scale to advance understanding of biology and improve health

UCL (University College London) is consistently ranked among the world's top ten universities (QS World University Rankings 2010 - 2021). Our excellence extends across all academic disciplines, from one of the world's foremost centres for research and teaching in the biological sciences to world-renowned centres for architecture (UCL Bartlett), education (UCL IOE) and fine art (UCL Slade School).

UCL is London's leading multidisciplinary university, with more than 13,000 staff and 43,000 students from 150 different countries. Founded in 1826 in the heart of London, UCL was the first university in England to welcome students of any religion and the first to welcome women on equal terms with men.

UCL Minds brings together UCL’s knowledge, insights, and ideas through events, activities, and digital content open to everyone. Find out what’s on UCL Minds: www.ucl.ac.uk/minds

The Trial Talk podcast explores how our work at the MRC Clinical Trials Unit at UCL is improving health in the UK and worldwide. In this series, we hear from world-leading experts about the studies we carry out. We delve into trials on cancer, infections and neurodegenerative diseases, explore how public and patient involvement shapes our work, and discover new ways to run smarter studies.

Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

Lung Cancer considered is funded in part by AstraZeneca, Genentech, Daiichi Sankyo, Inc., and Takeda

Are you a deep thinker with an open and rational mind? I enjoy sharing libertarian moral philosophy and entrepreneurial observations and advice. Welcome to the Openly Voluntary tribe!

New tracks tagged #Medical research